2026-04-21T08:10:00Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/ijpsdr.000046 2023-05-24 PTZ.IJPSDR:VOL9

Dasatinib-Induced Colitis: Risk of misdiagnosis of inflammatory bowel disease. A case report and review of the literature Graziana Arborea Anna Maria Valentini Stefania Marangi Nicoletta Labarile LTMaria Teresa Savino<p>Dasatinib is a potent tyrosine kinase inhibitor, in disease states associated with BCR/ABL 1, approved in 2006 for chronic myeloid leukemia treatment. This agent has been shown to exhibit broad off-target kinase inhibition and immunomodulating properties. These effects may be responsible for common adverse reactions (&gt; 15%) which include immunosuppression, cytopenias, pleural effusion and other fluid retention, diarrhea, and other gastrointestinal side effects.</p><p>Although gastrointestinal bleeding is a well-documented side effect, the presentation of colitis is an uncommon occurrence.</p><p>In most cases, it is hemorrhagic colitis, nonspecific colitis, or CMV-related colitis.</p><p>We report a 34-year-old male patient affected by CML in treatment with Dasatinib for approximately 1 year, who reported chronic diarrhea which progressed to suspected Dasatinib-induced colitis whose clinical, endoscopic, and histological findings overlapped those of Inflammatory Bowel Disease.</p> International Journal of Pharmaceutical Sciences and Developmental Research - Peertechz Publications 2023-05-24 Case Report https://doi.org/10.17352/ijpsdr.000046 en Copyright © Graziana Arborea et al.